Connect with us


AbbVie Becomes Partner of BaseLaunch

BaseLaunch, a Basel biotech incubator, gains support from AbbVie, joining Roche, Novo Nordisk, Johnson & Johnson, and CSL Behring. Operated by Basel Area Business & Innovation, BaseLaunch aids biotech startups without providing lab space. Since 2018, it has supported 24 companies, raising over $600 million. AbbVie’s investment strengthens ties to the European biotech ecosystem.




The Basel accelerator and incubator BaseLaunch, which finances and supports new biotech companies, is receiving further support: the US pharmaceutical company AbbVie is joining as a new partner.

This means that four of the world’s ten largest pharmaceutical companies (by market capitalization) are BaseLaunch’s partners. In addition to AbbVie, these include Roche, Novo Nordisk, Johnson & Johnson and CSL Behring. But the venture capital company Pureos Bioventures, the international law firm CMS and the South Korean-American Bridge Biotherapeutics also support the relatively young innovation factory in the tri-border area.

The incubator is operated by Basel Area Business & Innovation, the agency for location promotion and innovation support in the Basel region. It does not manage an incubator or offer laboratory space. Nevertheless, he has made it his mission to help scientists and entrepreneurs build successful biotech companies through other means.

How many millions Abbvie is investing in the start-up landscape in and around Basel was not disclosed

Since its launch in 2018, BaseLaunch has supported 24 early-stage companies with seed capital and supported them through further development through to Series A financing. In these six years, ten of the 24 companies have now raised a total of more than $600 million in capital from investors. Six companies currently have products in clinical development. Last year, T3 Pharma, which was also backed by BaseLaunch, was acquired by Germany’s Boehringer Ingelheim for $500 million. More promising start-ups are continually being added to BaseLaunch’s portfolio.

The dynamism at the Basel location is spreading internationally. Christian Schubert, Vice President and Head of AbbVie Ventures, Cambridge, MA (USA), comments on the commitment: “Our strategic investment in BaseLaunch will further strengthen our ties to the European biotech ecosystem. We look forward to working closely with the BaseLaunch team to promote the progress of innovative companies and medicines.”

Schubert, who is headquartered in Cambridge/Boston (USA), emphasized to | : “We are impressed by BaseLaunch’s track record and the unique business incubation model in Europe. We look forward to working even more closely with the European venture community in the coming years.”

Stephan Emmerth, Director of Business Development & Operations at BaseLaunch, Basel, added: “The partnership with AbbVie underlines the unique position of the Basel Area as Europe’s leading location for life sciences. AbbVie will support us as a global pharmaceutical company with high-quality support and advice. This is crucial for the successful development of our portfolio of innovative biotech companies.” BaseLunch’s portfolio includes Alentis, Cimeio and Phialogics.

Just 253 kilometers down the Rhine from Basel lies Abbvie’s research site in Germany and the former Knoll works in Ludwigshafen, the historical roots of the founding of AbbVie from the US pharmaceutical division of Abbott and an active ingredient from the Knoll-BASF joint venture, which the Americans have made into a mega-seller to this day: Humira.

Abbvie’s actual German headquarters are even a few kilometers further down the Rhine in the Hessian state capital Wiesbaden. From there, as well as from the US headquarters in Chicago, the investment decision to build an innovation center in Ludwigshafen was recently made. 150 million euros are being invested there, perhaps because they are hoping for a repeat of the Humira success?


(Featured image by Hans via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in transkript. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.